NCT06643130 Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia
| NCT ID | NCT06643130 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | JW Pharmaceutical |
| Condition | Hypertension |
| Study Type | INTERVENTIONAL |
| Enrollment | 162 participants |
| Start Date | 2024-12-02 |
| Primary Completion | 2026-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 162 participants in total. It began in 2024-12-02 with a primary completion date of 2026-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients with Hypertension and Dyslipidemia
Eligibility Criteria
Inclusion Criteria: * Patients with hypertension and dyslipidemia Exclusion Criteria: * The subject not meet the specified msBP and LDL-C level
Contact & Investigator
Minjung Kim
STUDY CHAIR
JW Pharmaceutical
Frequently Asked Questions
Who can join the NCT06643130 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06643130 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 162 participants.
Is NCT06643130 currently recruiting?
Yes, NCT06643130 is actively recruiting participants. Contact the research team at kmj@jwhealthcare.com for enrollment information.
Where is the NCT06643130 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06643130 clinical trial?
NCT06643130 is sponsored by JW Pharmaceutical. The principal investigator is Minjung Kim at JW Pharmaceutical. The trial plans to enroll 162 participants.